D l 1mt

Manufactured by Merck Group

D/L-1MT is a laboratory reagent used in research applications. It is a racemic mixture of the isomers D-1MT and L-1MT. The product is intended for use in scientific research and laboratory settings.

Automatically generated - may contain errors

Lab products found in correlation

Curved feeding needle, by Thermo Fisher Scientific (1 mentions) Methocel tween, by Merck Group (1 mentions) Methylcellulose, by Merck Group (1 mentions) Gp100, by Abcam (1 mentions) β actin ac 15, by Merck Group (1 mentions) β catenin, by Merck Group (1 mentions) Stat1, by Cell Signaling Technology (1 mentions) T erk, by Cell Signaling Technology (1 mentions) Wnt5a, by R&D Systems (1 mentions) P erk, by Cell Signaling Technology (1 mentions) Wnt3a, by R&D Systems (1 mentions) Folinic acid, by Merck Group (1 mentions) Theophylline, by Merck Group (1 mentions) Ib meca, by Merck Group (1 mentions)

5 protocols using d l 1mt

Indoleamine 2,3-Dioxygenase Inhibition in AIA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Indoleamine 2,3-dioxygenase was blocked using DL 1-MT (Sigma-Aldrich), which was prepared in drinking water (5 mg/ml) as described previously (8 (link)). The 1-MT drinking solution was administered 2 days before the first immunization until day 20 of AIA.

Chenna Narendra S., Chalise J.P., Biggs S., Kalinke U, & Magnusson M. (2018). Regulatory T-Cells Mediate IFN-α-Induced Resistance against Antigen-Induced Arthritis. Frontiers in Immunology, 9, 285.

+ Open protocol

+ Expand

Oral delivery of 1MT in CIA mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were given 400 mg/kg/dose (100μl total volume) D/L-1MT (Sigma) diluted in Methocel/Tween (0.5% Tween 80, 0.5% methylcellulose (v/v in water; Sigma) twice daily by oral gavage (p.o.) using a curved feeding needle (20G ×1 ½ in; Fisher) as described [17 (link)]. 1MT treatment was started the day before primary injection of collagen (day 0) and continued for the duration of the experiment.

Merlo L.M., Grabler S., DuHadaway J.B., Pigott E., Manley K., Prendergast G.C., Laury-Kleintop L.D, & Mandik-Nayak L. (2017). Therapeutic Antibody Targeting of Indoleamine-2,3-Dioxygenase (IDO2) Inhibits Autoimmune Arthritis. Clinical immunology (Orlando, Fla.), 179, 8-16.

+ Open protocol

+ Expand

Antibody Panel for Immunology Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

β-Catenin and PORCN(15G12.1) antibodies were purchased from Millipore, IDO (mIDO-48) from Biolegend, and HA (HA11) from Covance. PTEN, p-ERK, t-ERK, and Stat1 were purchased from Cell Signaling Technology and β-actin (AC-15) from Sigma. The following antibodies were purchased from BD Pharmingen: I-A^d (2G9), CCR7 (4B12), CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11c (HL3), CD16/CD32 (2.4G2), CD40 (3/23), CD45 (30-F11), CD80 (16-10A1), CD86 (GL1), FoxP3 (MF23), and PD-L1 (MIH5). Anti–GFP–Alexa Fluor 488 antibody were purchased from Invitrogen, Wnt5a from R&D Systems, and gp100 [EP4863(2 (link))] from Abcam. PCNA (F-2), S100β, TRP1 (H-90), TRP2 (D-18), and tyrosinase (H-109) antibodies were purchased from Santa Cruz Biotechnology. Wnt3a, Wnt5a, and IFNγ ligands were purchased from R&D Systems. Both the XAV939 and 1-MT inhibitors were purchased from Sigma Aldrich: D/L-1-MT for in vitro studies and D-1-MT for in vivo studies. Hydroxyamidine INCB024360 analogue (cat# 205493; ref. 29 (link)) and C59 inhibitor were purchased from MedKoo Biosciences and Cellagen Technology, respectively.

Holtzhausen A., Zhao F., Evans K.S., Tsutsui M., Orabona C., Tyler D.S, & Hanks B.A. (2015). Melnoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer immunology research, 3(9), 1082-1095.

+ Open protocol

+ Expand

Oral Gavage of D/L-1MT in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were given 400 mg/kg/dose (100μl total volume) of D/L-1MT (Sigma) diluted in Methocel/Tween (0.5% Tween 80, 0.5% methylcellulose (v/v in water)) twice daily by oral gavage (p.o.) starting at weaning (3 wk of age).

Merlo L.M., Pigott E., DuHadaway J.B., Grabler S., Metz R., Prendergast G.C, & Mandik-Nayak L. (2014). IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. Journal of immunology (Baltimore, Md. : 1950), 192(5), 2082-2090.

+ Open protocol

+ Expand

Combination Therapy for Cancer Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were given 400 mg/kg/dose (100µl total volume) of D/L-1MT (Sigma) diluted in Methocel/Tween (0.5% methylcellulose (w/v), 0.5% Tween 80 (v/v) in water) twice daily by oral gavage (p.o.); (33 (link)) 1, 10, or 25 mg/kg/dose (100µl total volume) of MTX (Hannah Pharmaceuticals) diluted in Methocel/Tween weekly p.o.; 0.5mg/kg IB-MECA (Sigma) diluted in saline daily i.p.; 10mg/kg theophylline (Sigma) diluted in Methocel/Tween daily p.o.; 1% difluoromethylornithine (DFM0; ILEX oncology) in the drinking water; 1 or 25mg/kg folinic acid (Sigma) diluted in Methocel/Tween daily p.o.; or a combination of 1MT, MTX, and the inhibitors. folinic acid and MTX were administered 8hr apart to avoid interference with their uptake (28 (link), 30 (link)). Control mice were given an equal volume of carrier alone (Methocel/Tween).

Pigott E., DuHadaway J.B., Muller A.J., Gilmour S., Prendergast G.C, & Mandik-Nayak L. (2014). 1-Methyl-Tryptophan Synergizes with Methotrexate to Alleviate Arthritis in a Mouse Model of Arthritis. Autoimmunity, 47(6), 409-418.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!